TAP Spectracef Launch Planned For Early 2001; Prevacid Sales Are $735 Mil.
Executive Summary
Abbott is predicting an early 2001 launch for TAP's cephalosporin antibiotic Spectracef, currently under review at FDA.
You may also be interested in...
Biaxin XL Gets 40% Of New Clarithromycin Scripts In December, Abbott Says
Abbott's once-daily Biaxin XL is cannibalizing close to half of the company's clarithromycin franchise, the company told investors during a Jan. 16 fourth quarter earnings call.
Biaxin XL Gets 40% Of New Clarithromycin Scripts In December, Abbott Says
Abbott's once-daily Biaxin XL is cannibalizing close to half of the company's clarithromycin franchise, the company told investors during a Jan. 16 fourth quarter earnings call.
Eisai/Janssen Aciphex Sales Closing In On $250 Mil. 13 Months After Launch
Janssen/Eisai's proton pump inhibitor Aciphex (rabeprazole) is closing in on $250 mil. in sales after 13 months on the market, Eisai U.S. Chairman Soichi Matsuno indicated Oct. 3 at a UBS Warburg Global Life Sciences Conference in New York City.